Witfire Elite · Clinical Catalysts · Registry Analysis The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed…
Read the analysis →Decision-useful coverage for executives, investors, regulators and scientists.
Witfire Elite · Litigation Risk Brief · GLP-1 Series No. 04 Novo Nordisk vs Eli Lilly: The Obesity Ad War Neither Side Can Win…
Witfire Elite · M&A Risk Brief · Deal No. 2026-07 Sun Pharma’s $11.75B Organon Deal: Platform Acquisition or Debt-Heavy Scale Bet? Shareholders cleared the…
Witfire Elite · Cardiometabolic Risk Brief · Pricing & Access Oral PCSK9 Inhibitor Approved: LIPFENDRA Lists at $315. Repatha Already Sells for $239. The…
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-07 Achieve’s Cytisinicline CRL: The Rejection That Was Priced Before It Arrived Same…
Original analysis connecting scientific evidence, regulatory decisions and market value.
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-06 The CMC Execution Crisis: Why Unicycive’s Second CRL Is a Warning Shot…
Witfire Elite · Licensing Risk Brief · CNS AlzeCure’s $2.2 Billion NeuroRestore Deal Is a Risk Transfer, Not a Victory AlzeCure did not prove…
Witfire Elite · Launch Execution · Competitive Strategy Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell. Viridian entered a $1.9 billion…
Witfire Elite Review, July 2026 -The Weakest Layer: The Stabilizer Ceiling, Eplontersen's CARDIO-TTRansform Miss, Unicycive OLC CRL.
Read the digital issue →
